Table 2. Primary reason for treatment modification during follow-up.

	Overall cohort			After Propensity matching
	Non-STR (n = 2713)	STR (n = 499)	p	Non-STR (n = 487)	STR (n = 487)	p
Patients without treatment modification	878 (32.4%)	291 (58.3%)	<0.001	181 (37.2%)	282 (57.9%)	<0.001
Reason for treatment modification, n (%)
Adverse event	553 (20.4%)	156 (31.3%)	<0.001	101 (20.7%)	154 (31.6%)	<0.001
Virological failure	154 (5.7%)	10 (2.0%)	<0.001	20 (4.1%)	10 (2.1%)	0.0951
Simplification	723 (26.6%)	0 (0%)	-	126 (25.9%)	0 (0%)	-
Other	405 (14.9%)	42 (8.4%)	<0.001	59 (12.1%)	41 (8.4%)	0.072

STR, single tablet regimen; Other includes: pregnancy (planned or ongoing), patient willingness, poor adherence, drug-drug interaction, enrollment in clinical trial, toxicity prevention such as switch from didanosine or stavudine to other drugs when the toxicities of these molecules were widely recognized.